Influenza A virus DNA vaccine H5N1 - Vical

Drug Profile

Influenza A virus DNA vaccine H5N1 - Vical

Alternative Names: Bird flu DNA vaccine - Vical; Influenza A (H5N1) DNA vaccine - Vical; Pandemic influenza plasmid DNA vaccine H5N1 - Vical; Vaxfectin-formulated plasmid DNA vaccine H5N1 - Vical; VCL-IPM1; VCL-IPT1

Latest Information Update: 07 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vical
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Influenza A virus H5N1 subtype

Most Recent Events

  • 07 Mar 2014 Influenza A virus DNA vaccine H5N1 - Vical is available for licensing as of 31 Dec 2011.
  • 31 Dec 2011 Suspended - Phase-I for Influenza-A virus H5N1 subtype (prevention) in USA (IM)
  • 24 Feb 2010 Efficacy and adverse events data from phase I trials in Influenza-A virus H5N1 subtype released by Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top